People on the Move: Biotechnology/Biopharmaceutical

James (Jim) Robinson is named president and CEO of Alkermes Inc. Robinson joined Alkermes from Astellas US LLC, where he served as president, Americas Operations with responsibility for the company’s operations in North and South America. Alkermes is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases.

Julien L. Pham, M.D., MPH, is now president of Genprex. Dr. Pham, who joined the company in 2016 as chief operating officer, will lead Genprex’s clinical development program as well as establish and grow strategic partnerships that contribute to its corporate objectives and innovative work across oncology and gene therapy.

John Celebi has been appointed president and CEO of Sensei Biotherapeutics Inc. Celebi served as the chief operating officer of X4 Pharmaceuticals where he established and oversaw the company’s oncology business strategy.

Dr. Eliel Bayever has joined OncoQuest Inc. as chief medical officer. Dr. Bayever was VP and head of oncology at Glenmark Pharmaceuticals.

Claudio Dansky Ullmann, M.D., is now chief medical officer of MaxCyte. Dr. Ullmann was most recently the senior VP and head of clinical development at Infinity Pharmaceuticals.

Dr. Peter Seufer-Wasserthal has been named chief business officer of Origenis GmbH. Prior to joining Origenis, he served as VP, business development, at Intrexon Corp.

Revital Mandil-Levin is now chief business development officer at CollPharm. Before joining CollPlant, from January 2014 to February 2018, Dr. Mandil-Levin served as VP, business development at NeuroDerm Ltd.

Ann D. Rhoads was appointed chief financial officer of Forty Seven Inc. Rhoads most recently served as executive VP and chief financial officer, treasurer, and secretary of Zogenix Inc.

Elizabeth “E.J.” Read, M.D., has become chief technology officer of Adicet Bio Inc. Prior to Adicet, she served as senior VP, product development at Medeor Therapeutics.

Luca Rastelli, Ph.D., is chief scientific officer of Kleo Pharmaceuticals Inc. Most recently, he was VP for oncology at BioXcel Therapeutics.

Francesco Marincola, M.D., joins Refuge Biotechnologies as chief scientific officer. He most recently served as a distinguished research fellow and strategist for immune oncology discovery at AbbVie.

Hoyoung Huh, M.D., Ph.D., has been appointed chairman of the board of directors at Pliant Therapeutics and Éric Lefebvre, M.D., has joined the company as chief medical officer. In addition to his role at Pliant, Dr. Huh serves as chairman to the board of directors for Geron Corp. and CytomX Therapeutics. He is also a director of Eidos Therapeutics and Rezolute. Prior to joining Pliant, Dr. Lefebvre was head of clinical research and development for non-alcoholic steatohepatitis (NASH) at Allergan.

Annie Teng, M.D., joined CANbridge Life Sciences as VP of clinical development and medical affairs and Janny Wang has started as director of quality assurance. Dr. Teng was head of biology and early development at Sanofi. Wang spent 11 years with Teva Pharmaceutical Industry subsidiary, Teva Pharmaceutical & Chemical, in China. CANbridge Life Sciences is a biopharmaceutical company focused on developing Western drug candidates in China and North Asia.